Alzheimer's disease (AD) has been well characterized by the presence of reactive microglia, often associated with ␤-amyloid (A␤) plaque deposition. The oligomeric form of A␤ peptide (A␤ o ) has neurotoxic effects in the presence of microglia and is suggested to potentiate proinflammatory changes in microglia in AD. Primary murine microglia cultures stimulated with A␤ o displayed increased protein phosphotyrosine and secreted tumor necrosis factor (TNF)-␣ levels which were attenuated by the Src/Abl inhibitor, dasatinib. Intracerebroventricular infusions of A␤ o into C57BL6/J mice stimulated increased microgliosis and protein phosphotyrosine levels that were also attenuated by dasatinib administration. The rodent findings were validated in human AD brains versus age-matched controls demonstrating reactive microglial association with A␤ o deposits and increased microglial protein phosphotyrosine and phospho-Src levels. These data suggest a role for A␤ o in microglial activation through a tyrosine kinase-dependant pathway both in rodent models and human disease. Use of a selective nonreceptor tyrosine kinase inhibitor such as dasatinib to attenuate microglial-dependent proinflammatory changes may prove to be an important step toward developing anti-inflammatory treatments for AD.
Introduction
The major histopathological markers of Alzheimer's disease (AD) are neurofibrillary tangles and ␤-amyloid (A␤) peptide containing plaques. Involvement of A␤ in the pathogenesis of AD is supported by the amyloid cascade hypothesis that has remained controversial over the years (Hardy and Higgins, 1992) . It suggests that mutations in amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) and abnormalities in APP metabolism may lead to accumulation and deposition of A␤ plaques and A␤-dependent synaptic and neuritic injury, altered signaling events, and neuron dysfunction subsequently leading to tangles, cell death, and dementia (Hardy, 2006; Hardy and Selkoe, 2002) . Because A␤ peptide forms a fibrillar core of the senile plaques in both sporadic and autosomal dominant disease it is hypothesized that fibrillar A␤ deposition is mechanistically critical for disease (Jarrett et al., 1993; Pike et al., 1993) .
Besides the accumulation of plaques and tangles it is well described in human disease and its transgenic mouse models that reactive microglia numbers are increased compared with nondemented controls and wild type mice, respectively (Akiyama and McGeer, 1990; Cras et al., 1990; Frautschy et al., 1998; McGeer et al., 1987; Sasaki et al., 2002; Stalder et al., 1999; Styren et al., 1990; Wegiel et al., 2001 Wegiel et al., , 2003 . The activated microglia are morphologically distinct from resting microglia and are commonly associated with A␤ fibril-containing plaques (Akiyama et al., 1999; Benzing et al., 1999; Itagaki et al., 1989; Mackenzie et al., 1995; Mattiace et al., 1990; Meyer-Luehmann et al., 2008; Morgan et al., 2005; Perlmutter et al., 1990; Sasaki et al., 1997) . Numerous in vitro studies have demonstrated that A␤ fibrils can directly stimulate microglia to acquire a proinflammatory phenotype (Banati et al., 1993; Combs et al., 2000 Combs et al., , 2001a Combs et al., , 2001b Del Bo et al., 1995; Giulian et al., 1995; Klegeris et al., 1997) .
However, recent data suggest that nonfibrillar, oligomeric A␤ conformations may be more reliable indexes of disease progression. For example, levels of soluble forms of A␤ have been shown to directly correlate with cognitive impairment and synaptic loss (Lue et al., 1999; McLean et al., 1999) . Much like their fibrillar derivatives, these soluble oligomers are neurotoxic, stimulate gliosis, produce cognitive dysfunction, and decrease long-term potentiation both in vitro and in vivo (Cleary et al., 2005; Klyubin et al., 2005; Lesné et al., 2006; Roher et al., 1996) . Indeed, up to 70% of diffuse plaques in nondemented aged individuals contain microglia (Sasaki et al., 1997) suggesting that microglial interaction with nonfibrillar peptide is common. Work from primates even indicates that gliosis precedes fibrillar plaque deposition (Martin et al., 1994) . Therefore, the fibrillar, insoluble form of the peptide may not be the only species mediating neuronal death/dysfunction. More importantly, the oligomeric peptide may represent a target for early disease therapy.
We previously demonstrated in vitro that A␤ oligomers stimulate a tyrosine kinase-based signaling response in microglia leading to acquisition of a reactive, neurotoxic secretory phenotype (Sondag et al., 2009) . In this work, we continue to define the ability of A␤ oligomers to activate microglia. Using primary murine microglia cultures we demonstrate that the Src/Abl inhibitor dasatinib is sufficient to attenuate the oligomer-stimulated increased in protein phosphotyrosine changes and increased cytokine secretion. More importantly, dasatinib was also able to attenuate the ability of oligomer to increase protein phosphotyrosine changes and microgliosis in vivo during intracerebroventricular infusion of the oligomeric species. Our study indicates that use of the Food and Drug Administration (FDA)-approved cancer drug, dasatinib, or related nonreceptor tyrosine kinase inhibitors, may be useful to attenuate A␤ oligomer-dependent proinflammatory changes in Alzheimer's disease.
Methods

Materials
Anti-oligomer antibody (I11) and anti-fibril antibody (OC) were previously described (Kayed et al., 2007) . The anti-oligomer antibody (A11) was purchased from Invitrogen (Camarillo, CA, USA). Anti-A␤, clones 6E10 and 4G8 were from Covance (Emeryville, CA, USA). The anti-Lyn antibody, anti-Src, anti-␣-tubulin antibodies, and horseradish peroxidase conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse tumor necrosis factor (TNF)-␣ enzyme linked-immunosorbent assay (ELISA) kit was obtained from R&D Systems (Minneapolis, MN, USA). Anti-phosphotyrosine (4G10) antibody was from Upstate (Temecula, CA, USA), HLA-DR Ab-1 (LN3) antibody was from NeoMarkers (Fremont, CA, USA) and anti-pLyn (396) antibody was purchased from Abcam (Cambridge, MA, USA). The Vector SG and Vector NovaRed kits were from Vector Laboratories, Inc. (Burlingame, CA, USA). Anti-CD68 was obtained from Serotec (Raleigh, NC, USA) and anti-pSrc antibody was purchased from Cell Signaling Technology (Danvers, MA, USA). The nonreceptor tyrosine kinase inhibitor, dasatinib was obtained from LC Laboratories (Woburn, MA, USA). The transgenic mouse line, strain 005864 B6.Cg-Tg(APPswe, PSEN1dE9)85Dbo/J was obtained from the Jackson Laboratory (Bar Habor, ME, USA).
Preparation of peptides
A␤1-42 was purchased from Bachem (Torrance, CA, USA) or American Peptide (Sunnyvale, CA, USA) for fibril and oligomer preparations, respectively. A␤1-42 peptide was dissolved in 1:1 acetonitrile-water, aliquoted, and dried. The aliquoted peptides were stored at Ϫ20°C until use. For oligomer preparation, each tube was dissolved in 50 L hexafluoroisopropanol (HFIP) and then diluted with 175 L of sterile water and stirred at room temperature for 48 hours. The peptide was then spun at 14,000 rpm, for 10 minutes and the supernatant quantified using the method of Bradford (Bradford, 1976) . For A␤ fibril preparations, A␤1-42 peptide was dissolved in deionized water and incubated for a week at 37°C. Before use, the fibril was mixed well and quantified using the Bradford assay.
Structural peptide analyses
For Western blot analysis of sodium dodecyl sulfatestable multimeric forms of oligomers, the peptide was diluted to different concentrations, separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blot using 6E10 (anti-A␤) as the primary antibody. For dot-blot analyses of oligomers and fibrils, 1 g each of A␤ oligomer or fibril were dot blotted onto polyvinylidene fluoride (PVDF) membrane and incubated with A11 (anti-oligomer) and 6E10 (anti-A␤) antibodies and analyzed via enhanced chemiluminescence (GE Healthcare, Piscataway, NJ, USA).
Tissue culture
Microglia cultures were derived from the brains of postnatal Day 1-3 C57BL/6J mice. Briefly, cortices were removed and trypsinized. The trypsin was inactivated in microglial growth media (DMEM/F-12 with L-glutamine [Invitrogen]) containing 10% heat-inactivated fetal bovine serum (FBS), 5% heat-inactivated horse serum, and antibiotics, penicillin, streptomycin, and neomycin (Gibco, Invitrogen, Carlsbad, CA, USA). The tissue was triturated and plated into tissue culture flasks. After 24 hours all media and cellular debris was replaced with fresh media. After 7 more days half of the media was replaced and cells were main-tained as a mixed glia culture until Day 14. At 14 days in vitro, microglia were shaken from the mixed glial culture at 200 rpm for 45 minutes and collected for use.
Cell stimulation
Microglia were placed into serum-free DMEM/F12 media for stimulations with A␤ oligomers or fibrils. To inhibit tyrosine kinases, cells were pretreated with drug or vehicle dimethylsulfoxide (DMSO) for 30 minutes before adding the appropriate concentrations of peptides. For ELISA analysis, cells were stimulated in 96-well plates (20,000 cells/ well, 75 L serum-free DMEM/F12) for 24 hours with 8 replicates per condition repeated 4 independent times. Experiments for Western blot analyses were for 5 minutes. After stimulation, cells were lysed in radioimmunoprecipitation assay buffer (RIPA) (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM Na 3 VO 4 , 10 mM NaF, 1 mM ethylenediaminetetraacetic acid [EDTA] , 1 mM ethylene glycol tetraacetic acid [EGTA], 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate) and quantified from 5 independent experiments.
ELISA
Media was collected from microglia following 24-hour stimulation for ELISA analysis. Levels of mouse TNF-␣ in the media were determined using commercially available ELISA kits according to the manufacturer's protocol (R&D Systems).
Cell viability assay
The 3[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide (MTT) reduction assay was performed to assess changes in cell survival. In brief, the media was removed from cells stimulated with or without A␤ and dasatinib and replaced with media containing MTT (100 g/mL) for 4 hours. The media was aspirated and the reduced formazan precipitate was dissolved in isopropanol and absorbances read at 560/650 nm via plate reader.
Western blot analysis
Cell lysates from 5-minute stimulations were resolved by SDS-PAGE and transferred to PVDF membranes. Western blots were blocked and incubated in anti-phosphotyrosine (4G10) antibody as primary antibody with ␣-tubulin as the loading control. Blots were washed followed by incubation with horseradish peroxidise (HRP)-conjugated secondary antibodies and antibody binding was detected via enhanced chemiluminescence.
Intracerebroventricular infusion of A␤1-42 oligomers and dasatinib
A␤ oligomers with or without dasatinib were infused into the right ventricle of C57BL/6 female mouse brains at 12 months of age. Mice were anesthetized with sodium pentobarbital (Nembutal, Ovation Pharmaceuticals, Lake Forest, IL, USA, 70 mg/kg) and a scalp incision made for stereotaxic placement of the cannula. Blunt end dissection caudally from the base of the scalp incision were performed to generate a small subcutaneous pocket for placement of an Alzet (model 1004, 0.25 L/hour delivery rate, Cupertino, CA, USA) osmotic pump in the subscapular region. A cannula (Brain Infusion Kit, Alzet) was stereotaxically placed into the right lateral cerebral ventricle at coordinates Ϫ1.0 mm mediolateral and Ϫ0.5 mm anterioposterior from bregma; Ϫ1.5 mm dorsal-ventral from skull. The cannulas were connected to subscapularly placed miniosmotic pumps (Alzet, model 1004) delivering either A␤ oligomers (1.6 g/day) or vehicle (4 mM (4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid) (HEPES), 250 g/mL human high density lipoprotein) with or without dasatinib (500 ng/kg per day) for 14 days. At the end of the infusion period, mice were euthanized, brains perfused with phosphate buffered saline (PBS)-CaCl 2 and rapidly collected. The right hemispheres were collected for cryosectioning and the left hemispheres were flash frozen in liquid nitrogen and lysed in radioimmunoprecipitation assay buffer for biochemical analysis.
Immunostaining mouse tissue
Right brain hemispheres were immersion fixed in 4% paraformaldehyde and all hemispheres per condition were embedded in a 15% gelatin matrix (in 0.1 M phosphate buffer) and again fixed in paraformaldehyde followed by exchanges of 30% sucrose in PBS over a several day time period. The fixed gelatin blocks were then flash frozen using a combination of dry ice and isomethylpentane, and 40-m sections were cut using a freezing microtome. Serial sections were collected and immunostained with the desired antibodies. Anti-phosphotyrosine (4G10) antibody was used at a dilution of 1:1000, CD68 at 1:500, anti-A␤ (4G8) at 1:500, A11 antibody at 1:250, OC antibody at 1:4000, and I11 antibody was used at 1:500 dilution. Primary antibody incubations were overnight at 4°C followed by 2-hour room temperature incubation with biotinylated secondary antibodies (Vector Laboratories) at 1:2000 dilution. Immunoreactivity was visualized using visible light chromogens VIP, Vector Blue, and 3,3=-Diaminobenzidine (DAB) (Vector Laboratories). For immunohistochemical quantification, 3 consecutive serial sections, (40 m apart) throughout the hippocampal region were chosen for densitometric analysis. Optical densities from the CA1 region were measured using Adobe Photoshop software (version 7.0, Adobe Systems, San Jose, CA, USA). The optical density of the entire CA1 region from a representative section was selected via marquee. The same size marquee was applied to all sections across all conditions to allow comparison of optical densities independent of area changes. All sections were immunostained at the same time to minimize background variability and background values in an unstained area of tissue for each section was set to 0 before measuring optical density values. The values for each section were averaged (3 sections per brain, 5-6 brains per condition) and plotted.
Double label immunofluorescence
For double label immunofluorescence staining, tissue was incubated in the desired primary antibodies and then corresponding Texas Red and fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (Santa Cruz Biotechnology). Tissue was counterstained with 4,6-diamidino-2-phenylindole (DAPI) and visualized using a Zeiss LSM-510 META Confocal Microscope (Thornwood, NY, USA).
Thioflavin staining
Mouse brain sections from A␤ oligomer and vehicle infused animals were stained with thioflavin (0.1 g/10 mL) and counterstained with DAPI (Invitrogen) to visualize the nucleus. To quench lipofuscin autofluorescence, the sections were then incubated in 0.1% Sudan Black for 30 minutes, rinsed with PBS and cover slipped using PBSglycerol (1:1).
Human tissue double staining
Human tissue was obtained from University of Washington Alzheimer Disease Research Center (ADRC, NIH P50AG05136) and was cut via freezing microtome (40 m) for immunostaining using DAB or Vector Red (Vector Laboratories) as the first chromogen. The sections were then stripped using 0.2 N HCl, 5 minutes and incubated with the second primary antibody for immunostaining using Vector Blue or Vector SG (Vector Laboratories) as the second chromogen.
Statistical analysis
Data are presented as mean Ϯ standard deviation. For in vitro and in vivo analyses, values statistically different from controls were determined using 1-way analysis of variance (ANOVA). The Tukey-Kramer multiple comparisons post test was used to determine p values. For statistical comparison of human AD tissue with age-matched controls, a paired t test was performed.
Results
A␤ oligomer stimulated increased total protein phosphotyrosine levels in primary microglia cultures that were attenuated by a nonreceptor tyrosine kinase inhibitor, dasatinib
In order to characterize the form of A␤ oligomer used in our studies, we first performed a structural analysis of the prepared peptide. Preparations were separated via 15% SDS-PAGE to demonstrate that the major detergent resistant multimer of A␤ migrated with an apparent molecular weight loosely correlating with a trimeric/tetrameric form of the peptide that was stable even after incubation at 37°C (Fig. 1A) . Larger amounts of loaded peptide demonstrated larger molecular weight multimers that were lesser species (Fig. 1A) . This low molecular weight migration pattern correlates approximately with the multimeric confirmations of A␤ oligomers isolated from human cerebral cortex as well as cerebrospinal fluid in which dimer/trimer forms of A␤ have been the primary forms observed (Klyubin et al., 2008; Shankar et al., 2008 Shankar et al., , 2011 Villemagne et al., 2010) . This demonstrates that several detergent-resistant species of oligomers are present in our preparation validating their use for subsequent cellular stimulations. In order to further confirm that the peptides were in a stable oligomeric conformation, dot blot analyses were performed after a period of 48 hours at 37°C. Oligomeric peptides were compared with fibrillar peptide. As expected, both fibrils and oligomers were immunodetected with an anti-A␤ antibody 6E10 (Fig. 1B) . However, only the oligomeric preparation was detected by the anti-oligomer antibody A11 (Kayed et al., 2003) (Fig. 1B) . We next determined the appropriate concentration of the oligomeric form of A␤ peptide (A␤ o ) for stimulating microglia. Our prior studies demonstrated that oligomeric peptide was sufficient to increase primary murine microglia total protein phosphotyrosine levels although the concentrations employed were above the physiologic range and included a larger range of multimeric species in the preparation (Sondag et al., 2009) . Primary murine microglia cultures were treated with varying concentrations of A␤ o for 5 minutes in order to assess the signaling response stimulated by peptide interaction. Oligomeric peptide stimulated an increase in total protein phosphotyrosine levels ( Fig. 2A ) that was significantly different from controls even as low as 100 nM (Fig. 2B) . Importantly this concentration is similar to that reported from human cerebrospinal fluid (CSF) and human cell culture conditioned medium (Podlisny et al., 1995; Seubert et al., 1992) . Due to the fact that different proteins are recognized with anti-phosphotyrosine antibodies, it is very common to see different overall Western blot banding patterns with different concentrations of ligands and different time courses of stimulation because protein phosphorylation/dephosphorylation is dynamically regulated during all of the signaling events initiated during any acute stimulation. Indeed, as can be seen from Fig. 2 , some phosphotyrosine immunoreactive bands steadily increase with dosage while others demonstrate a biphasic response. To further validate this point, we examined the changes of 2 specific tyrosine kinases in these experiments. The nonreceptor tyrosine kinase, Src, was elevated in its active, phosphorylated form at 100 nM A␤ o stimulation, while there was no change in the levels of active, Lyn kinase levels with either of the A␤ o doses (Fig. 2B) . Because of this complex, dynamic change we focused on the concentration that provides a maximal change for overall tyrosine phosphorylation rather than any particular molecular weight species.
In order to determine whether this A␤ stimulated increase in protein phosphotyrosine levels could be inhibited pharmacologically, a clinically relevant nonreceptor tyrosine kinase Src/Abl inhibitor, dasatinib, was used to assess its ability to attenuate the oligomer stimulated change in total protein phosphotyrosine levels (Das et al., 2006; Shah et al., 2004) (Fig. 2C) . As expected, dasatinib pretreatment significantly attenuated the A␤ o stimulated increase in total protein phosphotyrosine levels (Fig. 2D ). These data indicate that A␤ o is able to stimulate increased tyrosine kinase activity in primary murine microglia at physiologically relevant concentrations and this can be attenuated through the use of a nonreceptor tyrosine kinase inhibitor, dasatinib. 
A␤ oligomer stimulated increased TNF-␣ secretion from primary microglia cultures
To assess cell viability in presence of oligomeric A␤, primary microglia cultures were treated with different concentrations of A␤ o to validate that the 1 M concentration which demonstrated the most robust changes in protein phosphotyrosine levels was not toxic. The 10 M A␤ o proved to be slightly toxic to the cells by 24 hours of stimulation (Fig. 3A) justifying the use of 1 M for subsequent experiments and perhaps partially explaining the decrease in levels of protein phosphotyrosine observed after 10 M A␤ o stimulations ( Fig. 2A) . In order to determine whether the increase in tyrosine kinase activity was responsible for a change in secretory phenotype, microglia were stimulated with A␤ oligomers and fibrils with or without increasing concentrations of dasatinib for 24 hours. A concentration of 1 M 〈␤°was used for the stimulations based upon the fact that a robust stimulatory change in protein phosphotyrosine levels was observed with this concentration ( Fig. 2A) as well as the toxicity data from MTT analyses of microglia (Fig. 3A) . In addition, this represents a concentration closer to the levels found in brain (Podlisny et al., 1995; Seubert et al., 1992) offering a more physiologic impression of oligomer rather than fibril effects of A␤ during the progression of disease. Both fibrillar and oligomeric A␤ stimulated a significant increase in tumor necrosis factor (TNF)-␣ secretion that was attenuated in a dose dependent fashion (Fig. 3B) . Based upon the fact that dasatinib attenuated tumor necrosis factor-␣ secretion maximally at the lowest concentration employed, 100 pM, suggests that the drug concentration curve employed was already above the half maximal inhibitory concentration (IC 50 ) (Johnson et al., 2005) . These data demonstrated that oligomer A␤ stimulated a proinflammatory, cytokine secretory phenotype that was dependent upon propagation of the tyrosine-kinase based signaling response. The cell viability MTT reduction assay demonstrated that neither the peptide nor drug treatments were toxic to the microglia (Fig. 3C) .
A␤ oligomers stimulated tyrosine kinase dependent microgliosis in vivo
In order to validate the relevance of the in vitro findings, we next determined whether A␤ o could stimulate a tyrosine kinase associated microgliosis in vivo. The A␤ o were intracerebroventricularly infused into the right lateral ventricle of 12-month-old C57BL/6 mice for 14 days to stimulate gliosis in the absence or presence of coadministered dasatinib. A␤ o infused animals demonstrated a robust increase in microglial-like phosphotyrosine immunoreactivity that spatially correlated with increased reactive microglial CD68 immunoreactivity (Fig. 4A) . Densitometric analysis of the immunostaining demonstrated that dasatinib significantly attenuated the A␤ o -dependent increase in both phosphotyrosine (Fig. 4B) and CD68 (Fig. 4C) immunoreactivity. To validate the correlation between increased phosphotyrosine immunoreactivity and microgliosis, A␤ o -infused tissue was double labeled using anti-phosphotyrosine (4G10) antibody and CD68 antibody, along with control brain sections. CD68-positive microglia colocalized with phosphotyrosine immunoreactivity in the A␤-infused mouse brains (Fig.  4D) . In order to compare this acute model of A␤ oligomerstimulated increase in protein phosphotyrosine immunoreactivity to more chronic gliosis paradigms, microgliosis in infused brains was compared with that observed in a common transgenic mouse model of AD. This particular APP/ PS1 model is a double transgenic line that expresses chimeric mouse/human amyloid precursor protein (Ms/Hu APPswe) and a mutant human presenilin 1 (PS1dE9), allowing the mice to secrete human A␤ peptide. This mouse model of AD shows a progressive increase in A␤ deposition with age (Garcia-Alloza et al., 2006). As expected, CD68-positive microglia in this model but not C57BL/6J controls correlated with increased phosphotyrosine immunoreactivity (Fig. 4D ). This demonstrated that elevated phosphotyrosine immunoreactivity was a common presentation of reactive microglia across disease model paradigms including both acute and transgenic models.
However, it was not clear whether the phosphotyrosine immunoreactive, activated microglia in the A␤ oligomer infused brains correlated with oligomeric A␤ deposition. In order to determine whether microgliosis in the infusion model correlated with oligomeric A␤ deposits, immunohistochemical analyses of A␤ in infused brains was performed. Staining with the anti-A␤ antibody, 4G8, demonstrated immunoreactivity (Fig. 5A ) broadly correlating with the same localization pattern of CD68 and phosphotyrosine immunoreactivity observed in the peptide infused animals (Fig. 4A) . To determine whether the infused, immunodetected A␤ o had remained oligomeric rather than converting to fibrils, sections of treated brains were stained using anti-oligomer antibodies, A11 and I11 to detect oligomeric species. Both A11 and I11 antibodies demonstrated positive immunoreactivity in the A␤ o infused brains compared with vehicle-infused and control animals (Fig. 5B ). This was supported by the fact that A␤ o infused animals were negative for thioflavin staining and comparable with the vehicle treated group, suggesting that the immunodetected A␤ in infused brains had not fibrillized (Fig. 5C) . To further validate the use of anti-oligomer antibodies at recognizing nonfibril confirmations in situ, again, the transgenic APP/PS1 model was used. Immunostaining of brains from 12-month-old animals demonstrated robust immunoreactivity with anti-fibril antibody, OC, compared with control animals (Fig. 5D) . However, abundant immunoreactivity of nonfibril, oligomeric A␤ was also observed using A11, anti-oligomer antibody in these brains. Indeed, although OC and A11 immunoreactivity colocalized to the same plaque structures, each antibody often displayed unique immunoreactivities within plaques (Fig. 5D ). This not only indicates that plaques contain heterogeneous A␤ conformations but also suggests that anti-oligomer antibodies are useful for immunodetecting peptide conformations in situ, particularly in the infusion model employed.
AD brains demonstrated increased protein phosphotyrosine, A␤, active Src kinase, and active Lyn kinase levels compared with age matched controls
To further establish the correlation between A␤ oligomer levels and tyrosine kinase-dependent microgliosis during disease, we compared human AD tissue with age matched nondemented controls. As seen in the in vitro and in vivo rodent data, examination of temporal cortex from human AD brains demonstrated a significant increase in overall protein phosphotyrosine levels ( Fig. 6A  and B ). This correlated with a significant increase is phosphorylated active forms of the tyrosine kinase, Src, as well as Lyn kinase, in diseased brains versus their corresponding age-matched controls suggesting that the protein phosphotyrosine changes could be related to increased activity of the Src family of kinases ( Fig. 6C and  D) . AD and control tissue lysates were also analyzed via Western blot analyses to examine levels of multimeric forms of A␤ oligomers. Densitometric analysis of the multimeric SDS-stable species (Fig. 1A ) demonstrated that AD brains had a significantly higher level than agematched controls (Fig. 6A and B) correlating well with the changes in protein phosphotyrosine, active Src, and active Lyn levels.
HLA-DR-positive microglia from AD brains demonstrated increased phosphotyrosine immunoreactivity and heterogeneously localized with oligomeric A␤
In order to verify whether the changes in protein phosphotyrosine and A␤ oligomers correlated with microglial activation in the AD brains, immunostaining of fixed AD tissue was compared with age-matched controls. As expected, AD brains demonstrated defined, plaque-like deposits that were immunoreactive with the anti-oligomer (A11) antibody (Fig. 7A) . Although A11 positive deposits were not uniformly associated with activated microglia there were clear instances of HLA-DR (LN3) positive activated microglia directly associated with oligomeric deposits (Fig.  7A) . This supported the in vitro (Fig. 2 ) and in vivo (Fig. 4) rodent observations of the ability of oligomeric A␤ to stimulate microglia and suggested that a similar activation occurs during disease. To further support the rodent observations, the AD and control brain sections were immunostained to determine whether HLA-DR-positive, reactive microglia demonstrated increased protein phosphotyrosine levels indicative of increased tyrosine kinase activity. AD brains demonstrated increased immunostain- Fig. 4 . Intracerebroventricular infusion of oligomeric ␤-amyloid (A␤)1-42 stimulated increased protein phosphotyrosine and CD68 immunoreactivity that was attenuated by dasatinib. A␤ oligomer (1.2 mg/day) or vehicle control (human high density lipoprotein in artificial cerebrospinal fluid [CSF] ) in the presence or absence of drug (500 ng/kg per day) were infused into the right lateral ventricle of 12-month-old male C57BL6/J mice for 14 days (n ϭ 6). Brains were fixed, sectioned, and immunostained using antiphosphotyrosine (4G10) and CD68 antibodies. (A) Representative images from the dentate gyrus of the right hippocampus are shown. The arrow indicates the region imaged for the high magnification insets. Optical density (OD) of immunoreactivities for (B) phosphotyrosine and (C) CD68 were quantified from serial sections of the CA1 region (* p Ͻ 0.001 from control (c), vehicle (v), dasatinib (das), and A␤ with dasatinib). (D) A␤ oligomer-infused brains along with 12-month APP/PS1 and control mouse brains were double-immunostained using antiphosphotyrosine, 4G10 (red), and anti-CD68 (green) antibodies and counterstained with 4,6-diamidino-2-phenylindole (DAPI). Images shown are 40ϫ magnification.
ing for reactive microglia compared with age-matched controls (Fig. 7B ). More importantly, reactive HLA-DRpositive microglia colocalized with anti-phosphotyrosine immunoreactivity in both diffuse and clustered cell patterns supporting the idea that tyrosine kinase-dependent changes were a component of the microglial activation process during disease (Fig. 7B) .
HLA-DR positive microglia from AD brains displayed increased immunoreactivity for active, phosphorylated Src and Lyn kinases
To begin identifying the specific enzymes responsible for the increased protein phosphotyrosine levels, additional immunostaining of activated microglia in AD versus agematched control brains was performed. Based upon the Western blot analysis of increased levels of active phosphorylated Src in AD brains (Fig. 6 ) immunostaining of active Src was again compared with the related family member, Lyn. Double label immunostaining using anti-HLA-DR to identify reactive microglia verified that a heterogeneous portion of the activated microglia also demonstrated increased phosphorylated, active Src immunoreactivity compared with age-matched control brains (Fig. 8A) . A small amount of reactive microglia in AD versus control brains also demonstrated immunoreactivity for phosphorylated active, Lyn (Fig. 8C) . The immunostaining correlated well with the Western blot analysis changes (Fig. 6 ) and supported the idea that tyrosine kinase-dependent activation of microglia occurred in AD brains involving at least the nonreceptor kinase, Src. Dual label immunoflourescence and confocal imaging confirmed the colocalization of reactive microglia (using anti-HLA-DR antibody) and active Src immunoreactivity (Fig. 8B) as well as active Lyn immunoreactivity (Fig. 8D) .
Discussion
Our findings demonstrate that A␤ oligomers stimulate microglia activation in vitro via a tyrosine kinase-associated pathway that results in increased secretion of the proinflammatory cytokine, TNF-␣. It is possible to attenuate the oligomer-stimulated microglial phenotype change using a nonreceptor tyrosine kinase inhibitor, dasatinib. The in vitro observations were validated in vivo demonstrating that intracerebroventricular infusion of oligomeric A␤ also stim- ulated increased microgliosis via a tyrosine kinase-dependent mechanism that was attenuated by codelivery of dasatinib. Finally, the rodent findings correlated with reactive microglial increase in protein phosphotyrosine, p-Lyn and p-Src levels in AD brains compared with controls. To the best of our knowledge microglial pSrc and pLyn immunoreactivity in AD brains has not been reported prior thus identifying possible kinase targets for anti-inflammatory strategies. Also, the ability of oligomeric A␤ to stimulate these microglial changes in an in vivo mouse model now offers a system for addressing drug efficacy. Finally, we provide the first evidence that dasatinib, selected to target a particular tyrosine kinase, can be used to attenuate oligomeric A␤-dependent microgliosis. Collectively, these findings suggest that A␤ o can serve as a microglial activating ligand that leads to a proinflammatory phenotype and use of nonreceptor tyrosine kinase inhibitors may be an effective strategy to limit microglial-mediated changes during disease.
Although much of the data relies upon phosphotyrosine immunoreactivity, we appreciate that this type of assessment represents changes in a large number of diverse proteins. Indeed, it is likely that phosphatase activities are activated in parallel with kinase activities resulting in the cumulative presentation of protein phosphotyrosine levels observed with the Western blots or the immunostains. With both histology and Western blot analysis of phosphotyrosine immunoreactivity, it is difficult to predict what proteins are being assessed. In addition, the absolute profile of particular phosphotyrosine immunoreactive banding patterns by Western blot is very difficult to exactly reproduce from experiment to experiment because it can literally differ by collection times that vary by a few seconds. Indeed, although we perform all experiments as precisely identical Fig. 6 . Alzheimer's disease (AD) brains had elevated protein phosphotyrosine and active phospho-Src levels compared with age-matched controls. AD and age-matched control (c) temporal lobe lysates (n ϭ 6) were resolved by 10% SDS-PAGE and Western blotted using (A) anti-phospho-Tyr (4G10), anti-␤-amyloid (A␤) (6E10), anti-␣-tubulin (loading control) antibodies, (C) anti-Lyn, antiphospho-Lyn (Tyr396), anti-Src, and antiphospho-Src antibodies. Optical density of (B) Total phospho-Tyr or A␤ multimers and (D) pLyn and pSrc from 6 AD and age-matched control brain blots were normalized to their respective ␣-tubulin blots or total protein levels (Lyn/Src) then averaged and graphed (Ϯ SD) (* p Ͻ 0.001).
as possible, there are sometimes differences even in basal levels of protein phosphotyrosine banding patterns. For this reason, we are careful not to place emphasis on any particular molecular weight species when performing phosphotyrosine Western blots but rather on overall differences always compared with their appropriate vehicles/controls.
In addition, we appreciate that immunostaining quantitation employed in the current study could benefit from additional means of quantitation. We have relied on immunostaining to perform the quantitation in this study based upon our impression from other studies in the laboratory that the hemisphere that receives the infusion has the more robust response compared with the contralateral side. Therefore, quantitative analysis is usually performed on only the infused side which we collected by fixation for this study. Future work could include an additional means of quantitation of microgliosis-associated changes including ELISA, kinase activity assays, and Western blotting.
It is important to point out that although the microgliosis observed from the in vivo component of the data resulted from infusion of oligomeric A␤, we have not demonstrated that the microglial changes observed are due to a direct stimulation of microglia by A␤. This is an intrinsic limitation of the in vivo approach and the staining is necessarily correlative with the in vitro data set. Nevertheless, we feel that the histologic observations of the infused brains do offer some insight into possible events that may occur during disease even though we cannot definitively state that oligomers are directly stimulating a microglial increase in tyrosine kinase activity. Because there is, to the best of our knowledge, no accepted stimulus for the increase in phosphotyrosine immunoreactivity in the AD mouse models or the human disease we offer the suggestion that oligomeric A␤ may be 1 of the ligands involved. In addition, the oligomeric infusion paradigm at least allows us to state that the increase in protein phosphotyrosine immunoreactivity is associated with an oligomeric stimulation in vivo which is mechanistically a bit more rigorous than immunostaining transgenic or human diseased brains and colocalizing A␤ and phosphotyrosine immunoreactivity and hypothesizing that A␤ is the stimulus responsible for the immunoreactivity change.
We have found that an oligomeric preparation of A␤ corresponding roughly to the size of SDS-stable trimer/ tetramers at initial stimulation can drive microgliosis via a tyrosine kinase-dependent mechanism that correlates with a similar change in tyrosine phosphorylation in human diseased brains. Despite the fact that the oligomeric A␤ was delivered in an high density lipoprotein solution to ensure its stability as an oligomeric preparation while in the pump, it is possible that the multimeric species changed after infusion into the brain over the time course of 14-day administration resulting in higher molecular weight species. However, immunohistochemical analyses using anti-oligomer antibodies to observe for oligomeric A␤ immunoreactivity strongly suggests by the thioflavin negative, A11/ I11 positive nature of the deposited A␤ that the peptide was retained in an oligomeric and not fibrillar form. We cannot exclude the possibility that higher order multimers and possibly some undetected fibrils did accumulate in the tissue during the infusion period along with, perhaps, codeposition of endogenous A␤. With the understanding that there may be some multimeric species of A␤ involved, along with the SDS-stable trimeric/tetrameric infused A␤, we suggest that the changes observed in microgliosis and the ability of dasatinib to attenuate those changes remain novel and relevant to A␤-dependent microglial changes during disease.
With regard to human disease, we certainly do not exclude the likelihood that fibrillar deposits of A␤ are also potent stimuli of microglia. Increased protein phopho-tyrosine staining from both AD brains and transgenic mouse models (Frautschy et al., 1998; Wood and Zinsmeister, 1991) have characterized microglial activation in association with A␤ plaques. Furthermore, prior work has demonstrated that fibrils also stimulate microglia in vitro via tyrosine kinasemediated mechanisms (Combs et al., 1999; McDonald et al., 1997) . However, our histologic analysis of human brains demonstrated that some reactive microglia were associated with oligomeric A␤ as well, a finding not widely reported. In addition, many phosphotyrosine immunoreactive microglia in diseased brains were not associated with any observable A␤ deposits suggesting that nondeposited A␤ oligomers or other molecules could be activating these cells as well. Therefore, we propose that oligomers are 1 of the Fig. 8 . A population of Alzheimer's disease (AD) brain microglia was immunoreactive for phospho-Lyn and phospho-Src. AD and control temporal lobe sections were immunostained using anti-HLA-DR antibody to identify microglia, antiphospho-Lyn-396 antibody to identify activated Lyn kinase, and antiphospho-Src antibody to identify activated Src kinase. (A) p-Src (blue)/HLA-DR (brown) double label and (C) p-Lyn (gray)/HLA-DR (red) double label images are shown. Images are representative of 3 cases each. AD and control temporal lobe sections were also double-labeled using immunoflourescence using (B) anti-HLA-DR (green) and anti-pSrc (red) antibodies or (D) anti-HLA-DR (green) and anti-pLyn (red) antibodies. stimuli driving microgliosis during disease but recognize a likely role of fibrils as well as possible still unnamed ligands.
Despite the fact that the specific stimuli driving microgliosis during disease may be heterogeneous, a common finding from our rodent in vitro and in vivo findings and AD brains is the increase in protein phosphotyrosine levels. Our prior in vitro work has demonstrated that specific nonreceptor tyrosine kinase activities including Lyn and Syk are involved in the oligomer-dependent activation of microglia (Sondag et al., 2009 ) which correlated well with the increased phosphotyrosine immunoreactivity observed in the intracerebroventricular infused animals. We have not yet characterized the extent of specific kinase changes in the in vivo model but we are aware that numerous tyrosine kinases are expressed in microglia and it is likely that the temporal profile of kinase activities changes during chronic oligomer stimulation. During disease, fibril or other ligand stimulations may also initiate additional changes in specific tyrosine kinase activities that will be superimposed upon oligomer-mediated responses (Sondag et al., 2009 ). Therefore, we have not attached any crucial proinflammatory significance to a particular kinase activity at this point other than to validate that in human disease, active forms of nonreceptor tyrosine kinases, Src and Lyn, are increased in reactive microglia consistent with the rodent data. Indeed, the microglial phospho-Src and phospho-Lyn immunoreactivity changes we observed in the AD brains is, to the best of our knowledge, a new contribution to the field by beginning to identify particular kinase activities that may be responsible for the increase in phosphotyrosine immunoreactivity. Future efforts to identify particular populations of microglia that are immunoreactive for activated tyrosine kinases in correlation with colocalization to oligomeric or fibrillar A␤ may offer insight into mechanistic reasons for microglial heterogeneity of activation during disease.
This common change of increased forms of active nonreceptor tyrosine kinases in the rodent and human findings served as the rationale for selecting a somewhat broad specificity agent, dasatinib, for its ability to attenuate the function of several different kinases, in particular the Src family members (Das et al., 2006; Lombardo et al., 2004) . The ability of dasatinib to limit protein phosphotyrosine changes and cytokine secretion suggests that targeting kinase activity is a viable anti-inflammatory strategy for treating AD. It is interesting to note that limiting tyrosine kinasedependent microgliosis is not the only attractive reason for targeting these enzymes. For instance tau phosphorylation is modulated via activity of the tyrosine kinase Abl modulating Cdk5 activation in a transgenic mouse model of AD (Alvarez et al., 2004; Cancino et al., 2011) . Very recently, another tyrosine kinase inhibitor anticancer drug, imatinib, has been shown to target gamma-secretase activating protein as a therapeutic approach for Alzheimer's disease in a rodent model (He et al., 2010) . Not surprisingly, recruitment of Src and Abl tyrosine kinases to APP has been demonstrated (Trommsdorff et al., 1998) . Our prior work has also verified an increased association of Src with APP in human diseased brains (Austin et al., 2009 ). Although we have focused on a specific oligomer-stimulated mechanism of proinflammatory microgliosis in AD that is nonreceptor tyrosine kinase-dependent, it appears that the heterogeneous mixture of changes during disease offers the possibility that inhibition of this class of kinases will be attractive from a number of different therapeutic perspectives.
Validation that an orally available, Food and Drug Administration-approved drug, dasatinib, is efficacious in our in vivo study supports the idea of therapeutic tyrosine kinase inhibition for AD. Dasatinib (commercially, Sprycel) is used for treating chronic myeloid leukemia (Shah et al., 2004) and has the ability to cross the blood brain barrier (Porkka et al., 2008) . It attenuates proinflammatory microgliosis and inhibits disease relevant nonreceptor tyrosine kinases. Further studies involving transgenic mouse models of AD and use of dasatinib and/or other nonreceptor tyrosine kinase inhibitors will shed light on the mechanism(s) of microglial activation during disease and confirm that tyrosine kinase activity is an important target for attenuating disease.
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